Related Experiment Video
Updated: Jan 4, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines
Jan Torben Schille1,2, Ingo Nolte2, Eva-Maria Packeiser1,2
1Department of Medicine, Clinic III-Hematology, Oncology, Palliative Medicine, University of Rostock, 18057 Rostock, Germany.
Abstract:
Current therapies are insufficient for metastatic prostate cancer (PCa) in men and dogs. As human castrate-resistant PCa shares several characteristics with the canine disease, comparative evaluation of novel therapeutic agents is of considerable value for both species. Novel isoquinolinamine FX-9 exhibits antiproliferative activity in acute lymphoblastic leukemia cell lines but has not been tested yet on any solid neoplasia type. In this study, FX-9's mediated effects were characterized on two human (PC-3, LNCaP) and two canine (CT1258, 0846) PCa cell lines, as well as benign solid tissue cells. FX-9 significantly inhibited cell viability and induced apoptosis with concentrations in the low micromolar range. Mediated effects were highly comparable between the PCa cell lines of both species, but less pronounced on non-malignant chondrocytes and fibroblasts. Interestingly, FX-9 exposure also leads to the formation and survival of enlarged multinucleated cells through mitotic slippage. Based on the results, FX-9 acts as an anti-mitotic agent with reduced cytotoxic activity in benign cells. The characterization of FX-9-induced effects on PCa cells provides a basis for in vivo studies with the potential of valuable transferable findings to the benefit of men and dogs.
Insights
Novel isoquinolinamine FX-9 shows promise against prostate cancer (PCa) in both humans and dogs. This anti-mitotic agent effectively reduced cancer cell viability and induced apoptosis, with less impact on normal cells.
Area of Science:
- Comparative oncology
- Pharmacology
- Molecular biology
Background:
- Metastatic prostate cancer (PCa) in humans and dogs shares similarities, making comparative studies valuable for developing new therapies.
- Current treatments for metastatic PCa are insufficient, necessitating the exploration of novel therapeutic agents.
- Isoquinolinamine FX-9 has demonstrated antiproliferative effects in leukemia cell lines but its efficacy against solid tumors is unknown.
Purpose of the Study:
- To investigate the anti-cancer effects of novel isoquinolinamine FX-9 on human and canine prostate cancer (PCa) cell lines.
- To compare the efficacy and specificity of FX-9 between malignant PCa cells and benign solid tissue cells.
- To characterize the mechanism of action of FX-9 in PCa cells.
Main Methods:
- FX-9 treatment of human (PC-3, LNCaP) and canine (CT1258, 0846) PCa cell lines.
- Assessment of cell viability and induction of apoptosis following FX-9 exposure.
- Evaluation of FX-9 effects on non-malignant human fibroblasts and chondrocytes.
- Microscopic analysis to observe cellular morphology changes, including multinucleation and mitotic slippage.
Main Results:
- FX-9 significantly inhibited cell viability and induced apoptosis in both human and canine PCa cell lines at low micromolar concentrations.
- The anti-cancer effects of FX-9 were comparable across human and canine PCa cell lines.
- FX-9 demonstrated reduced effects on non-malignant chondrocytes and fibroblasts, indicating potential specificity.
- FX-9 exposure resulted in the formation of enlarged multinucleated cells via mitotic slippage, suggesting an anti-mitotic mechanism.
Conclusions:
- FX-9 exhibits potent anti-prostate cancer activity in both human and canine models.
- The compound acts as an anti-mitotic agent with a favorable therapeutic window, showing less toxicity to benign cells.
- These findings support further in vivo investigation of FX-9 as a potential treatment for metastatic prostate cancer in both species.
